Press Release

PhRMA Announces Support for Seven-Day Script Limit on Opioid Medicines for Acute Pain

PhRMA September 27, 2017

Washington, D.C. (September 27, 2017) – Today, Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement:

“As part of our commitment to advancing a multifaceted solution to address the opioid crisis, today PhRMA is announcing it supports policies limiting the supply of opioids to seven days for acute pain treatment. We are taking this step because we believe the worsening opioid epidemic demands additional solutions, with new protections for patients. Too often, individuals receive a 30-day supply of opioid medicines for minor treatments or short-term pain. Overprescribing and dispensing can lead to patients taking opioids longer than necessary or to excess pills falling into the wrong hands.

“Appropriate script limits, when combined with improved prescriber education and better coverage of treatment alternatives, can help ensure proper prescribing and reduce the risk of abuse. Given the scope and scale of this crisis, we believe this is the right thing to do.”

Ubl discussed the need for appropriate script limits during a hearing held today by the President’s Commission on Combating Drug Addiction and the Opioid Crisis, Chaired by Gov. Chris Christie (R-NJ). The meeting featured testimony from biopharmaceutical executives who are working on innovative pain and addiction therapies.

PhRMA has been working closely with the Commission, the National Institutes of Health (NIH), and the Food and Drug Administration to develop a public-private partnership that will accelerate the development of non-opioid, non-addictive pain medicines and medication assisted treatments for long-term addiction recovery. The public-private partnership would allow increased information sharing and collaboration between government and industry to speed the drug development process.

With today’s announcement, PhRMA supports State and Federal policies that:

  • Limit the supply for first time, acute pain opioid prescriptions to seven days
  • Include a list of circumstances under which a prescriber may deviate from any mandate (e.g. for cancer-related pain, hospice care or accessibility obstacles)
  • Affirm exemptions for medication assisted treatments for patients seeking long-term addiction recovery in addition to counseling and mental health support

About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:  
www.PhRMA.org 
www.Innovation.org 
www.GoBoldly.com
www.Facebook.com/PhRMA 
www.Twitter.com/PhRMA